Claim Missing Document
Check
Articles

Found 4 Documents
Search

Antimicrobial Effect of Ethanol Extract of Red Betel Leaf (Piper crocatum) on the Growth of Klebsiella pneumoniae bacteria Edbert Wielim; Marwoto .; Zulaika Nur Afifah
Nexus Biomedika Vol 6, No 1 (2017): Nexus Biomedika
Publisher : Nexus Biomedika

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (13.864 KB)

Abstract

Background:Red betel leaf (Piper crocatum) as a herbal plant has been exist through generations, and can be trusted to heal many diseases such as diabetes mellitus, cancer, and hemoroid. According to the research, red betel leaf has some compounds that can be used as antibiotics for example like, flavonoid, alkaloid, tanin, and essential oil. Klebsiella pneumoniae is one cause of nosocomial infection, which Klebsiella pneumoniae has been resistant to certain antibiotics known as Extended Spectrum b Lactamase (ESBL). The purpose of this research is to know the effect of Ethanol extract red betel the Growth of Klebsiella pneumoniae. Methods: This research was an laboratory experimental with post test only with contro group design, conducted in Microbiology Laboratory Faculty of Medicine of Sebelas Maret University, Surakarta. The sample were ATCC standard of Klebsilla pneumonia, clinics isolate of ESBL, and clinics isolate of non ESBL. ESBL and biochemical test were attempted first. After ESBL were proven, the next step was preliminary test and according to preliminary test, 70% ethanol extract of red betel leaf was used for this research. Negative control was ethanol 70%, positive control was cefoperazone+sulbactam, and treatment group was 70% ethanol extract of red beter leaf. Kruskal Wallis and Mann Whitney were used for analyse the data in this research. Results: According to the research, there was no inhibiton zone that formed on negative control, ethanol extract 70% of clinics isolate of non ESBL, and clinics isolate of ESBL. Inhibition zone formed on ethanol extract 70% of ATCC (10,3 0,57 mm), positive control of ATCC (37,5 1,15 mm), positive control of clinics isolate of non ESBL (36,1 5,63 mm), and positive control of clinics isolate of ESBL (23,9 1,19 mm). Kruskal Wallis showed there was statistically significant difference to all the sample (p= 0,000). Mann Whitney showed there was statistically difference between ethanol extract 70% of ATCC with clinics isolate of ESBL and clinics isolate of non ESBL (p=0,01), positive control of clicnis isolate of ESBL with ATCC (p= 0,219), and ethanol extract 70% of ATCC with positive control of ATCC (p =0,043). Conclusion : There was a different between the growth of all the sample of Klebsiella pneumoniae. Keywords:ethanol extract of red betel leaf, Klebsiella pneumoniae.
Clinical Characteristics and Progression of Osteogenesis Imperfecta Type III: A Case Series Edbert Wielim; Chyntia; Regina Suriadi; I Wayan Bikin Suryawan
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 5 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i5.1268

Abstract

Background: Osteogenesis imperfecta (OI) is a rare genetic disorder primarily affecting bone formation, leading to increased bone fragility and fractures. OI Type III is characterized by severe clinical manifestations, including multiple fractures, skeletal deformities, and short stature. This case series describes the clinical characteristics and progression of three patients diagnosed with OI Type III, highlighting the impact of early intervention with zoledronic acid on their outcomes. Case presentation: This study presents three cases of OI Type III in female patients. Two patients (Patient A and Patient R) were diagnosed at birth with multiple fractures and received zoledronic acid treatment starting at three months of age. The third patient (Patient D) presented with fractures later in infancy and began treatment at one year of age. All patients demonstrated hallmark features of OI Type III, including blue sclerae, short stature, and progressive skeletal deformities. However, the two patients who received earlier treatment with zoledronic acid showed better mobility and fewer fractures compared to the patients who started treatment later. Conclusion: This case series emphasizes the importance of early diagnosis and intervention in OI Type III. Zoledronic acid appears to be effective in reducing fracture rates and improving mobility in these patients. Further studies with larger sample sizes are needed to confirm these findings and optimize treatment strategies for OI Type III.
Beyond Microcephaly: Semilobar Holoprosencephaly with Marked Macrocephaly due to Severe Congenital Hydrocephalus, Brachycephaly, and Hyponatremia – A Case Report Cynthia Cynthia; Edbert Wielim; Regina Suriadi; Putu Siska Suryaningsih
Open Access Indonesian Journal of Medical Reviews Vol. 5 No. 5 (2025): Open Access Indonesian Journal of Medical Reviews
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/oaijmr.v5i5.768

Abstract

Holoprosencephaly (HPE) is a rare, complex brain malformation arising from incomplete prosencephalon cleavage, typically associated with microcephaly and facial dysmorphism. Coexisting severe hydrocephalus leading to macrocephaly in HPE, particularly the semilobar type, presents a distinct clinical picture. Hyponatremia often complicates neurological conditions involving increased intracranial pressure, potentially worsening prognosis. The aim of this case report is to meticulously describe the clinical presentation, diagnostic evaluation, management approach, and early outcomes of this rare and complex neonatal neurological disorder. A male neonate, born at 35+3 weeks gestation to a mother with severe preeclampsia, presented with marked macrocephaly (head circumference 50 cm), a prominent fontanel, and bilateral sunset eyes. Initial CT scan confirmed hydrocephalus. Subsequent evaluation and a repeat CT scan at one month revealed brachycephaly (cephalic index 98) and semilobar holoprosencephaly. Head circumference progressed to 64 cm by the time of ventriculoperitoneal (VP) shunt surgery at approximately 5 weeks of age. Laboratory investigations showed hyponatremia (120 mEq/L), hyperkalemia, and hypochloremia. At three months, the patient exhibited significant growth and developmental delays and malnutrition. In conclusion, this case highlights an unusual presentation of semilobar HPE characterized by severe congenital hydrocephalus causing marked macrocephaly, rather than microcephaly, complicated by brachycephaly and significant hyponatremia. Early, comprehensive diagnostic evaluation and multidisciplinary management are crucial in such complex neurodevelopmental disorders to address multifaceted challenges and attempt to optimize outcomes.
Clinical Characteristics and Progression of Osteogenesis Imperfecta Type III: A Case Series Edbert Wielim; Chyntia; Regina Suriadi; I Wayan Bikin Suryawan
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 5 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i5.1268

Abstract

Background: Osteogenesis imperfecta (OI) is a rare genetic disorder primarily affecting bone formation, leading to increased bone fragility and fractures. OI Type III is characterized by severe clinical manifestations, including multiple fractures, skeletal deformities, and short stature. This case series describes the clinical characteristics and progression of three patients diagnosed with OI Type III, highlighting the impact of early intervention with zoledronic acid on their outcomes. Case presentation: This study presents three cases of OI Type III in female patients. Two patients (Patient A and Patient R) were diagnosed at birth with multiple fractures and received zoledronic acid treatment starting at three months of age. The third patient (Patient D) presented with fractures later in infancy and began treatment at one year of age. All patients demonstrated hallmark features of OI Type III, including blue sclerae, short stature, and progressive skeletal deformities. However, the two patients who received earlier treatment with zoledronic acid showed better mobility and fewer fractures compared to the patients who started treatment later. Conclusion: This case series emphasizes the importance of early diagnosis and intervention in OI Type III. Zoledronic acid appears to be effective in reducing fracture rates and improving mobility in these patients. Further studies with larger sample sizes are needed to confirm these findings and optimize treatment strategies for OI Type III.